Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation
Latest Information Update: 20 May 2025
At a glance
- Drugs HSK 39004 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Haisco Pharmaceutical Group
Most Recent Events
- 20 May 2025 New trial record